I suspect that you are correct. The author has published a variety of work including on dietary supplements and herbs.BillTre said:I could not tell from the paper where their funding came from. It would not surprise me if some of it were from some kind of growers group.
Some companies have made investments in being able to generate and use genomic data.
Hi Tom, (and everyone else)Tom.G said:
Since you indicate that you have done some initial research, perhaps contacting the Author(s) directly would get results.Oldman too said:could you or anyone else make a suggestion on finding a credible source or "search parameter" that might be useful ?
From quickly browsing the article, it looks like the researchers studied only exocannabinoids (specifically only cannabinoids from hemp). The article does not even mention endocannabinoids.Oldman too said:Hi Tom, (and everyone else)
I'm reading the links you've posted, a particular aspect of the uses and benefits in the study have me confused. That being, how do the researchers sort out the differences between Endo and Exo Cannabinoids and their relation to the study results ?
I'm usually marginally okay at searching things for myself but this question gets consistently marginal results, could you or anyone else make a suggestion on finding a credible source or "search parameter" that might be useful ?
Thanks, that helps me frame my question to the Author a little clearer. It's nearly impossible, from a layman's perspective to read these papers and get more than the basic idea... very basic.Ygggdrasil said:From quickly browsing the article, it looks like the researchers studied only exocannabinoids (specifically only cannabinoids from hemp). The article does not even mention endocannabinoids.
The acknowledgments have sparse details but no funding info. This is weird for an ACS paper nowadays. Not trying to accuse them of anything untoward, but something to keep in mind. FTA:BillTre said:I could not tell from the paper where their funding came from.
Cannabinoids are chemical compounds found in the cannabis plant. They act on the body's endocannabinoid system, which regulates various physiological processes such as pain, mood, and inflammation.
Studies have shown that cannabinoids can inhibit the replication of SARS-CoV-2, the virus that causes COVID-19, by blocking its entry into host cells. They do this by binding to specific receptors on the cell surface, preventing the virus from attaching and entering.
Not all cannabinoids have been studied for their potential to block the entry of SARS-CoV-2. However, early research has shown that certain cannabinoids, such as CBD and CBG, have a high binding affinity for the receptors that the virus uses to enter cells.
While the research is still in its early stages, some studies have shown promising results in using cannabinoids to treat COVID-19. However, more research is needed to fully understand the potential benefits and risks of using cannabinoids as a treatment for this virus.
At this time, there is not enough evidence to support using cannabinoids as a preventive measure against COVID-19. It is important to continue following recommended guidelines such as wearing masks, practicing social distancing, and washing hands regularly to prevent the spread of the virus.